Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

A Multi-Center, Open-Label, Pharmacokinetic Drug Interaction Study of Erenumab and a Combined Oral Contraceptive in Healthy Females.

Xu Y, Gabriel K, Wang Y, Zhou Y, Eisele O, Vutikullird A, Mikol DD, Lee E.

CNS Drugs. 2019 May;33(5):513-522. doi: 10.1007/s40263-019-00626-2. Erratum in: CNS Drugs. 2019 May 6;:.

2.

[Information Gaps in Package Inserts Cause Insufficient Patient Information on Correct Handling of Transdermal Patches].

Lampert A, Haefeli WE, Seidling HM.

Dtsch Med Wochenschr. 2019 Mar;144(5):e36-e41. doi: 10.1055/a-0722-7419. Epub 2019 Mar 5. German.

PMID:
30836398
3.

Evaluation of Potential Drug-Drug Interaction Between Delayed-Release Dimethyl Fumarate and a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women.

Zhu B, Nestorov I, Zhao G, Meka V, Leahy M, Kam J, Sheikh SI.

Clin Pharmacol Drug Dev. 2017 Nov;6(6):604-613. doi: 10.1002/cpdd.377. Epub 2017 Aug 7.

4.

The pharmacokinetics of 12-week continuous contraceptive patch use.

Lavelanet AF, Rybin D, White KO.

Contraception. 2017 Jun;95(6):578-585. doi: 10.1016/j.contraception.2017.03.002. Epub 2017 Mar 8.

PMID:
28285154
5.

Norelgestromin/ethinyl estradiol intravenous infusion formulation optimization, stability and compatibility testing: A case study to overcome polysorbate 80 interference in chromatographic analysis.

Abdallah IA, Hammell DC, Hassan HE, Stinchcomb AL.

J Pharm Biomed Anal. 2016 Jun 5;125:145-53. doi: 10.1016/j.jpba.2016.03.024. Epub 2016 Mar 19.

PMID:
27018506
6.

Ethinyl estradiol and levonorgestrel in a transdermal contraceptive delivery system.

Sriprasert I, Stanczyk FZ, Archer DF.

Expert Opin Pharmacother. 2015;16(12):1901-9. doi: 10.1517/14656566.2015.1056733.

PMID:
26194214
7.

Dolutegravir Has No Effect on the Pharmacokinetics of Oral Contraceptives With Norgestimate and Ethinyl Estradiol.

Song IH, Borland J, Chen S, Wajima T, Peppercorn AF, Piscitelli SC.

Ann Pharmacother. 2015 Jul;49(7):784-9. doi: 10.1177/1060028015580637. Epub 2015 Apr 10.

8.

Transdermal contraception methods: today's patches and new options on the horizon.

Nelson AL.

Expert Opin Pharmacother. 2015 Apr;16(6):863-73. doi: 10.1517/14656566.2015.1022531. Review.

PMID:
25800084
9.

A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.

Gruber D, Skřivánek A, Serrani M, Lanius V, Merz M.

Contraception. 2015 Feb;91(2):105-12. doi: 10.1016/j.contraception.2014.10.003. Epub 2014 Oct 13.

PMID:
25453582
10.

Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.

Hofmann B, Reinecke I, Schuett B, Merz M, Zurth C.

Int J Clin Pharmacol Ther. 2014 Dec;52(12):1059-70. doi: 10.5414/CP202064.

11.

Lack of a clinically important pharmacokinetic interaction between sofosbuvir or ledipasvir and hormonal oral contraceptives norgestimate/ethinyl estradiol in HCV-uninfected female subjects.

German P, Moorehead L, Pang P, Vimal M, Mathias A.

J Clin Pharmacol. 2014 Nov;54(11):1290-8. doi: 10.1002/jcph.346. Epub 2014 Jun 24.

PMID:
24925712
12.

Lurasidone drug-drug interaction studies: a comprehensive review.

Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A.

Drug Metabol Drug Interact. 2014;29(3):191-202. doi: 10.1515/dmdi-2014-0005. Review.

PMID:
24825095
13.

Metabolic effects of the contraceptive skin patch and subdermal contraceptive implant in Mexican women: a prospective study.

Hernandez-Juarez J, Garcia-Latorre EA, Moreno-Hernandez M, Moran-Perez JF, Rodriguez-Escobedo MA, Cogque-Hernandez G, Julián-Nacer R, Hernandez-Giron X, Palafox-Gomez R, Isordia-Salas I, Majluf-Cruz A.

Reprod Health. 2014 Apr 26;11:33. doi: 10.1186/1742-4755-11-33.

14.

Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.

Bifano M, Sevinsky H, Hwang C, Kandoussi H, Jiang H, Grasela D, Bertz R.

Antivir Ther. 2014;19(5):511-9. doi: 10.3851/IMP2718. Epub 2013 Dec 17.

PMID:
24343001
15.

Budget impact analysis of 8 hormonal contraceptive options.

Crespi S, Kerrigan M, Sood V.

Am J Manag Care. 2013 Jul 1;19(7):e249-55.

16.

Skin patch and vaginal ring versus combined oral contraceptives for contraception.

Lopez LM, Grimes DA, Gallo MF, Stockton LL, Schulz KF.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD003552. doi: 10.1002/14651858.CD003552.pub4. Review.

PMID:
23633314
17.

Antimüllerian hormone levels decrease in women using combined contraception independently of administration route.

Kallio S, Puurunen J, Ruokonen A, Vaskivuo T, Piltonen T, Tapanainen JS.

Fertil Steril. 2013 Apr;99(5):1305-10. doi: 10.1016/j.fertnstert.2012.11.034. Epub 2012 Dec 20.

PMID:
23260855
18.

Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.

Sidney S, Cheetham TC, Connell FA, Ouellet-Hellstrom R, Graham DJ, Davis D, Sorel M, Quesenberry CP Jr, Cooper WO.

Contraception. 2013 Jan;87(1):93-100. doi: 10.1016/j.contraception.2012.09.015. Epub 2012 Oct 19.

PMID:
23083525
19.

Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women.

Upreti VV, Hsiang CB, Li L, Xu X, LaCreta FP, Boulton DW.

Diabetes Obes Metab. 2012 Dec;14(12):1155-7. doi: 10.1111/j.1463-1326.2012.01635.x. Epub 2012 Jul 9.

PMID:
22776778
20.

Combined hormonal contraceptives and venous thromboembolism: putting the risks into perspective.

Raymond EG, Burke AE, Espey E.

Obstet Gynecol. 2012 May;119(5):1039-44. doi: 10.1097/AOG.0b013e31825194ca.

PMID:
22525916

Supplemental Content

Loading ...
Support Center